Vancouver, British Columbia -- This week, HYTN Innovations, a pharmaceutical manufacturer specializing in products containing psychoactive and psychotropic compounds, announced that wholesale cannabis products previously exported to Germany during the prior quarter have now been successfully released for sale in the market.
The release follows completion of required import, quality control, and market release procedures for Germany’s regulated medical cannabis market. Things went so well that HYTN even accepted a reorder for additional wholesale product.
"The successful release of product into the German market is a significant commercial milestone,” said Elliot McKerr, HYTN CEO. “It validates that our GMP platform meets the stringent requirements of one of the world’s most tightly regulated medical cannabis markets. The acceptance of a reorder is a positive indicator as we continue toward building recurring international revenue channels.”
HYTN believes the successful German market release supports its strategy of expanding pharmaceutical-grade cannabis sales into highly regulated international markets.
